
Early-stage biotech targeting muscle loss in patients with end-stage renal disease.
Industry: Health Care
First Day Return: -3.2%
Industry: Health Care
| IPO Data | |
|---|---|
| IPO File Date | 06/20/2014 |
| Offer Price | $11.00 |
| Price Range $14.00 - $16.00 | |
| Offer Shares (mm) | 5.0 |
| Deal Size ($mm) | $55 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 10/15/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $55 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Brisbane, CA, United States |
| Founded | 2012 |
| Employees at IPO | 15 |
| Website www.atarabio.com | |